Thales, European Leader in Quantum Physics and Artificial Intelligence, Opens InnovDays 2019
27.11.2019 20:36:00 EET | Business Wire | Press release
Thales launched InnovDays in 2012 as a way for its customers and partners to gain exclusive insights into the technological excellence of its research facilities. Since then, successive InnovDays events have turned the spotlight on the latest technological innovations developed by more than 29,500 Thales engineers and researchers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191127005575/en/
Thales InnovDays 2019 (Photo: Thales)
InnovDays: building a trusted future through science
InnovDays is a reflection of Thales's objective of leveraging science and high technology to build a future we can all trust. By harnessing the unprecedented precision and power of quantum physics and augmenting the performance of its systems thanks to artificial intelligence, Thales is developing the new generation of technologies that will shape the world of tomorrow.
"InnovDays is an illustration of Thales's outstanding technological capabilities and the passion displayed by our 29,500 engineers for helping our customers step up to society's major challenges through innovation." Marko Erman, Chief Technology Officer.
As an expert in critical systems, Thales is conducting in-depth research into both digital technologies and deep tech solutions to develop a portfolio of products based on a common core of technological building blocks. At InnovDays on 27, 28 and 29 November 2019, Thales will present a total of 70 practical applications of this research centred around the following themes:
Round tables:
-
Thursday 28 November:
- 8.30 am: How can we make AI trustable?
- 1.30 pm: Sovereignty in the digital age
-
Friday 29 November:
- 8.30 am: High tech and climate change: friend or foe?
- 11.00 am: The strategy and the future of air transport
- 1.30 pm: The second quantum revolution starts now!
Star guests from the world of science and industry will be taking part in these round table sessions, including Albert Fert (Nobel Prize in Physics 2007), Jean-Marc Jancovici (Founder and President of The Shift Project), Alexandre de Juniac (IATA Director General and CEO) and Pascale Senellart (research director at the Centre for Nanoscience and Nanotechnology, Paris-Saclay University, Paris-Sud University, CNRS).
Proposed press tours at InnovDays 2019
- Tomorrow's cities
- The future of transport
- Biometrics
- The Cloud
- Big Data
- Tomorrow's connectivity in the civil world
- Tomorrow's connectivity in the world of defence
- Air defence of the future
- Land and naval defence of the future
- The augmented soldier
- Secure identities and data for citizens and businesses
|
On 27, 28 and 29 November 2019, the Thales YouTube channel will feature live coverage of the round table sessions and some of the most popular demonstrations. |
From sensors that are up to 10,000 more accurate to ultra-secure communications, quantum technologies are set to push back the boundaries of physics and unleash previously unexploited properties of matter.
An aircraft flying from Paris to New York with only an inertial navigation system to guide it could determine its location to within a few kilometres. With future quantum sensors, it could land with a precision of within a metre. In other fields, quantum sensors could detect tumours that are invisible today, or provide a basis for developing new sources of energy.
Quantum physics relies on radically new concepts and ways of manipulating matter. Quantum sensors, like quantum communications and quantum computing, are currently under the microscope in the laboratories operated by Thales and its academic partners (CNRS, Université Paris-Saclay, etc.) at the Saclay research and technology cluster, south of Paris.
On 26 November 2019, Thales and its academic and research partners are organising a presentation at Saclay to highlight European excellence in quantum research: from cold atoms to flawed diamonds and superconductors, scientific progress in quantum physics has the potential to harness unexploited properties of matter and unleash a whole host of new opportunities.
Thales is working on these new properties to develop the next generation of quantum sensors, relying on the exact same technological building blocks as quantum computers. Quantum encryption too, could soon lead to communication systems that are completely secure and trustworthy.
Thales has also been selected to take part in the European OPENQKD initiative as part of the Austrian Institute of Technology (AIT) consortium chosen by the European Commission to install infrastructure in several European countries to test quantum communication networks.
Navigating intelligently among millions of aircraft movements: Thales presents the brain of tomorrow's aircraft.
Ultimately, quantum technologies will provide untold benefits for avionics systems, including order-of-magnitude improvements in navigation precision. But the immediate truth is that solutions are needed now to deal with the growth in air traffic, which is expected to have doubled by 2030.
This is the thinking behind PureFlyt, developed by Thales as the brain of tomorrow's aircraft, a fully connected cockpit that will significantly increase aircraft performance.
PureFlyt will be unveiled in Toulouse on 25 November. One of the core innovations that makes PureFlyt a game-changer is its ability to draw on both onboard and open-world data, such as weather information, so that the aircraft trajectory can be permanently controlled, adapted and enhanced, resulting in optimised flight, decreased fuel consumption and a better flying experience for both passengers and crew.
|
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gemalto). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
Thales Group
Download photos
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005575/en/
Contact information
PRESS
Thales, Media relations
Cédric Leurquin
+33 (0)1 57 77 90 93
cedric.leurquin@thalesgroup.com
Thales, Media relations
Alice Pruvot
+331 57 77 89 52
alice.pruvot@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
